Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.86 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.86 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113078 | 0.93 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9CYP1A2 | |
| SCHEMBL18448102 | 0.87 | PTGS2 (0.72) | PTGS2PTGS1PDPK1CYP2C9CYP3A4 | |
| SCHEMBL2697564 | 0.87 | PTGS2 (0.65) | PTGS2PTGS1PDPK1CYP2C9CYP1A2 | |
| SCHEMBL6247556 | 0.86 | PTGS2 (0.86) | PTGS2PTGS1PDPK1CYP2C9CYP1A2 | |
| SCHEMBL14345166 | 0.86 | PTGS2 (0.86) | PTGS2PTGS1PDPK1CYP2C9CYP1A2 | |
| SCHEMBL4588503 | 0.86 | PTGS2 (0.86) | PTGS2PTGS1PDPK1CYP2C9CYP1A2 | |
| SCHEMBL5694394 | 0.86 | PTGS2 (0.86) | PTGS2PTGS1PDPK1CYP2C9CYP1A2 | |
| SCHEMBL12213580 | 0.86 | PDPK1 (0.73) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL2698251 | 0.86 | PTGS1 (0.76) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL14747609 | 0.86 | PTGS2 (0.74) | PTGS2PTGS1PDPK1CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005046615-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005018563-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004103286-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CHOLIMERGIC AGENT | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004093816-A2 | COMPOSITIONS COMPRISING A SELECTIVE COX-2 INHIBITOR AND A CALCIUM MODULATING AGENT | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093811-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM ION CHANNEL BLOCKER FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |